SeptAlign
Commercial- Indications
- Nasal septal deviation, Nasal airway obstruction
Company intelligence / Profile preview
Spirair
Peninsula/San Francisco Bay Area*, California, United Statesspirair.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
Spirair has developed SeptAlign, a minimally invasive, bioabsorbable implant for the mechanical correction of nasal septal deviation. The device received FDA 510(k) clearance in 2024 and is now commercially available in the United States. Clinical results from a feasibility study showed significant improvement in symptoms of nasal obstruction at 12 months post-procedure, with a strong safety and tolerability profile[3][6][7].
- Therapeutic areas
- OtherPulmonology
- Modalities
- DeviceBioabsorbable implant
- Industry
- Implantable Medical Devices
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Spirair.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Spirair.